Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06382311 · ClinicalTrials.gov registry record · Phase 1
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 991
- Enrollment target
NCT06382311 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 991 participants.
The verdict
NCT06382311, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 991 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.
Interventions
- BIOLOGICAL Flu Pandemic mRNA_Dose level 1
- BIOLOGICAL Flu Pandemic mRNA_Dose level 2
- BIOLOGICAL Flu Pandemic mRNA_ Dose level 3.
- BIOLOGICAL Flu Pandemic mRNA_ Dose level 4
- BIOLOGICAL Flu Pandemic mRNA_Dose level 5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 991 participants |
| Start Date | 2024-04-18 |
| Est. Completion | 2026-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06382311
The ClinicalTrials.gov registry entry for NCT06382311 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 991 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Flu Pandemic mRNA_Dose level 1 is the first listed.
NCT06382311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06382311 about?
NCT06382311 is a clinical study titled "A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults". The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.
What is the current status of trial NCT06382311?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 991 participants. The study started on 2024-04-18. Estimated completion is 2026-01-13.
What interventions are being tested in trial NCT06382311?
The interventions under investigation include: Flu Pandemic mRNA_Dose level 1 (BIOLOGICAL), Flu Pandemic mRNA_Dose level 2 (BIOLOGICAL), Flu Pandemic mRNA_ Dose level 3. (BIOLOGICAL), Flu Pandemic mRNA_ Dose level 4 (BIOLOGICAL), Flu Pandemic mRNA_Dose level 5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06382311?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.